Lupus Nexus Launches to Advance Personalized Lupus Treatments and Cure

Lupus Nexus Launches to Advance Personalized Lupus Treatments and Cure

By, Admin 23 May 2025

Lupus Research Alliance Launches Landmark Initiative: Lupus Nexus Foundational Analyses

New York, NY — May 2025 — The Lupus Research Alliance (LRA), the world’s largest non-governmental, nonprofit funder of lupus research, has launched a major scientific initiative: the Lupus Nexus Foundational Analyses. This ambitious project aims to create one of the most comprehensive and accessible lupus research datasets ever assembled.

Key Highlights

  • Purpose: Generate molecular datasets using biospecimens from the Lupus Landmark Study, a cornerstone of the Lupus Nexus.
  • Scope: Integrate molecular data with robust clinical information, including:
  • Clinician-reported outcomes
  • Patient-reported outcomes
  • Significance: First effort of this scale by a private nonprofit in the lupus research field.

About Lupus and the Research Challenge

  • Lupus is a complex, chronic autoimmune disease affecting multiple organs.
  • The disease presents differently in each individual, making diagnosis and treatment highly variable.
  • Despite decades of research, personalized treatment options remain limited due to gaps in understanding disease heterogeneity.

About the Lupus Nexus

Launched in 2023, the Lupus Nexus is a unique:

  • Registry
  • Biorepository
  • Information exchange platform: DREAM (Data Repository, Exchange and Analytics platforM)

Objective: Catalyze lupus research and accelerate the development of precision medicine strategies.
Foundational Analyses: A Major Milestone

Conducted in collaboration with:

  •  Azenta
  • Cmbio (formerly CosmosID)
  • iRepertoire
  • LabCorp
  • MitogenDx/University of Calgary
  • Sano Genetics
  • Standard BioTools

Scientific Components:

  • Whole genome sequencing
  • RNA sequencing
  • Proteomics
  • Microbiome profiling

What makes this unique:

  • Integration of multiple scientific data types with detailed real-world clinical data.

Expert Perspectives

The Foundational Analyses are a bold investment in the future of lupus research and a major milestone for the Lupus Nexus,”
— Devon Kelly, Director of the Lupus Nexus, LRA
By pairing molecular analyses with clinical context, we’re giving scientists the tools they need to generate new hypotheses and ultimately drive meaningful breakthroughs for people living with lupus.
Now, with the addition of Foundational Analyses, researchers will, for the first time, have access to molecular data integrated with real-world data.”
— Virginia Pascual, M.D., Gale and Ira Drukier Director of Children’s Health Research, Weill Cornell Medical College

Data Access and Timeline

  • Initial datasets will be available through DREAM by the end of 2025.
  • Additional releases to follow in subsequent years.
  • Researchers will gain access to:
  • All raw data from Foundational Analyses
  • Data generated from custom studies using Lupus Nexus biospecimens

Initial Presentation

• First data presented at:

16th International Congress on Systemic Lupus Erythematosus (LUPUS 2025)

Location: Toronto

  • Date: May 20, 2025
  • Abstract: #PV153
  • Understanding Lupus
  • Affects millions globally.
  • Caused by autoantibodies attacking the body’s own tissues.
  • Can damage:
  • Kidneys
  • Brain
  • Heart
  • Lungs
  • Skin
  • Blood
  • Joints
  • 90% of patients are women, typically aged 15–45.
  • Disproportionately impacts Black, Latinx, Indigenous, Asian, and Pacific Islander populations.

About the Lupus Research Alliance

  • World’s largest nonprofit funder of lupus research
  • Mission: Transform treatment and find a cure
  • Approach:
  • Fund innovative science
  • Support top research talent
  • Advance discovery for better diagnostics and therapies

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!